Evidence map›Paper›PMID 17564966›Full record

ArticleAmerican journal of human genetics2007

A new genetic disorder in mitochondrial fatty acid beta-oxidation: ACAD9 deficiency.

M He, S L Rutledge, D R Kelly, C A Palmer, G Murdoch, N Majumder, R D Nicholls, Z Pei, P A Watkins, J Vockley

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in American journal of human genetics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 123 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Case Report: Homozygous mutation in theFrontiers in medicine · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Coenzyme Q inMarine drugs · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

M HeChildren's Hospital of Pittsburgh, Department of Pediatrics, University of Pittsburgh, School of Medicine, Pittsburgh, PA, 15213, USA.
S L Rutledge
D R Kelly
C A Palmer
G Murdoch
N Majumder
R D Nicholls
Z Pei
P A Watkins
J Vockley
Children's Hospital of Pittsburgh · USChildren's of Alabama · USJohns Hopkins University · USKennedy Krieger Institute · USUniversity of Pittsburgh · US

Funding

Rare Liver Disease NetworkU54DK078377 · NIDDK · CHILDREN'S HOSPITAL OF DENVER · PI SOKOL, RONALD J. · 2006 to 2010
$2.4M
MOLECULAR CHARACTERIZATION OF ACYL-COA DEHYDROGENASESR01DK045482 · NIDDK · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI VOCKLEY, GERARD · 1993 to 2004
$1.2M
NIDDK NIH HHS R01 DK045482NIDDK NIH HHS R01 DK45482NIDDK NIH HHS U54 DK078377
6 · The paper itself

Abstract

The acyl-CoA dehydrogenases are a family of multimeric flavoenzymes that catalyze the alpha,beta -dehydrogenation of acyl-CoA esters in fatty acid beta -oxidation and amino acid catabolism. Genetic defects have been identified in most of the acyl-CoA dehydrogenases in humans. Acyl-CoA dehydrogenase 9 (ACAD9) is a recently identified acyl-CoA dehydrogenase that demonstrates maximum activity with unsaturated long-chain acyl-CoAs. We now report three cases of ACAD9 deficiency. Patient 1 was a 14-year-old, previously healthy boy who died of a Reye-like episode and cerebellar stroke triggered by a mild viral illness and ingestion of aspirin. Patient 2 was a 10-year-old girl who first presented at age 4 mo with recurrent episodes of acute liver dysfunction and hypoglycemia, with otherwise minor illnesses. Patient 3 was a 4.5-year-old girl who died of cardiomyopathy and whose sibling also died of cardiomyopathy at age 21 mo. Mild chronic neurologic dysfunction was reported in all three patients. Defects in ACAD9 mRNA were identified in the first two patients, and all patients manifested marked defects in ACAD9 protein. Despite a significant overlap of substrate specificity, it appears that ACAD9 and very-long-chain acyl-CoA dehydrogenase are unable to compensate for each other in patients with either deficiency. Studies of the tissue distribution and gene regulation of ACAD9 and very-long-chain acyl-CoA dehydrogenase identify the presence of two independently regulated functional pathways for long-chain fat metabolism, indicating that these two enzymes are likely to be involved in different physiological functions.

Indexed as

Acyl-CoA Dehydrogenase, Long-ChainAdolescentBase SequenceBrainChildDNA Mutational AnalysisFatty AcidsFemaleGene Expression RegulationGenome, HumanHumansLipid Metabolism, Inborn ErrorsMaleMitochondrial DiseasesMolecular Sequence DataMuscle, SkeletalACADVL protein, humanAcyl-CoA Dehydrogenase, Long-ChainFatty AcidsRecombinant ProteinsRNA, Messenger

Identifiers

PMID17564966
PMCPMC1950923
OpenAlexW2077491834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.